New combo therapy aims to cure hepatitis b in over half of patients
NCT ID NCT05769816
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The study builds on earlier work that achieved cure in up to 50% of certain patients, and aims to improve that rate to over 50% overall.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-PD-1 antibody (a type of immunotherapy) and nucleos(t)ide analogues (antiviral drugs)
What this could lead to
If successful, this combination could help more than half of patients achieve a functional cure, meaning the virus is controlled without lifelong medication.
What could go wrong
This is a phase 2 trial with only 120 participants, so results are preliminary. The anti-PD-1 antibody may cause immune-related side effects, and the cure rate may not reach the hoped-for 50%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 2nd affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact